US Bancorp’s Agile Therapeutics AGRX Stock Holding History

US Bancorp’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3	Closed	-$14K	–	3905
2020 Q2	$14K	Buy	3 +1	+50%	+$5.2K	﹤0.01%	2990
2020 Q1	$9K	Buy	+2	New	+$11.5K	﹤0.01%	3073

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

US Bancorp's AGRX Position: Q3 2020 in Review

US Bancorp sold out of Agile Therapeutics (AGRX) in Q3 2020, closing a stake of 3 shares — an estimated $14K sold.

US Bancorp first reported a position in AGRX in Q1 2020 and held it in 2 quarters. The position peaked at $14K in Q2 2020. 75 funds tracked by Wall St. Rank hold AGRX as of Q3 2020.

US Bancorp reported no remaining Agile Therapeutics position as of Q3 2020 after selling out during the quarter.
US Bancorp sold 3 Agile Therapeutics shares in Q3 2020, an estimated $14K.
US Bancorp first reported a position in Agile Therapeutics in Q1 2020 and held it in 2 quarters.
US Bancorp's Agile Therapeutics position peaked at $14K in Q2 2020.
75 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2020.

Based on US Bancorp's 13F filing for Q3 2020, filed 10 Nov 2020.